Specifically, the first one has been deeply investigated as a component of chimeric molecules for delivering therapeutic miRNAs to Axl-positive tumors [116] and the second one as a targeting agent for effective GBM therapy, thanks to its dual function for both BBB crossing and cancer targeting [117]. The gene discussed is AXL; the disease is cancer.